ClinicalTrials.gg
CompletedNCT07043283Updated Jun 26, 2026

A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects

A Phase 1 interventional study of Ebronucimab in Healthy Subjects, sponsored by Akeso. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a phase I clinical study to evaluate the pharmacokinetics (PK) similarity of single dose subcutaneous injection of Ebronucimab with different production processes in Chinese healthy male subjects.

Read the detailed description

This is a randomized, double-blind, parallel controlled, phase I clinical study to evaluate the pharmacokinetics (PK) similarity of single dose subcutaneous injection of Ebronucimab with different production processes in Chinese healthy male subjects. A total of approximately 230 Chinese healthy male subjects are planned to be enrolled.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects fully understand the purpose, content, process, and potential adverse events of the trial, voluntarily participate in the trial, and sign an form before any trial procedure begins.
  • Weight: 60\~72kg; (BMI) ≥ 19 and ≤ 26 kg /m² for healthy Chinese male subjects.
  • Fasting LDL-C level\<4.1mmol/L.
  • Fasting triglycerides\<3.42mmol/L.
  • Required to voluntarily adopt effective measures as specified in the protocol throughout the entire trial period and within 3 months after receiving the product, and avoid sperm donation.

Exclusion criteria

Exclusion Criteria:

  • 12 months prior use of PCSK9 inhibitors treatment.
  • Allergic to the components of Ebronucimab and any monoclonal antibodies.
  • History of important organ transplantation (such as heart, lung, liver, kidney, etc.).
  • Abnormal vital signs during screening period and before randomization.
  • Investigators believe that other factors may disqualify individuals from participating in the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    Ebronucimab 150mg (after the change)

    Ebronucimab 150mg Single subcutaneous injection into the abdomen.

    Drug: Ebronucimab

  • Experimental
    Ebronucimab 150mg (before the change)

    Ebronucimab 150mg Single subcutaneous injection into the abdomen.

    Drug: Ebronucimab

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum (peak) plasma concentration (Cmax)

    Assess the Cmax of Ebronucimab.

    Time frame: Baseline till last follow-up visit (up to day 43)

  2. Area under curve (AUC)

    Assess the AUC of Ebronucimab.

    Time frame: Baseline till last follow-up visit (up to day 43)

Secondary outcomes

  1. Incidence of adverse events (AE)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: After the first administration till last follow-up visit (up to day 43)

  2. Immunogenicity index

    Number and percentage of subjects with detectable anti drug antibodies (ADA) and neutralizing antibodies (Nab) after treatment.

    Time frame: Baseline till last follow-up visit (up to day 43)

  3. Proprotein convertase subtilisin/kexin type 9 (PCSK-9) concentration

    Percentage change in PCSK-9 concentration compared to baseline.

    Time frame: Baseline till last follow-up visit (up to day 43)

  4. Serum low-density lipoprotein cholesterol (LDL-C) concentration

    The change value and percentage of serum LDL-C concentration compared to baseline.

    Time frame: Baseline till last follow-up visit (up to day 43)

07

Study locations

1 site
  • Zhejiang Xiaoshan Hospital
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Feb 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jun 29, 2025
StartActual
Oct 20, 2025
Primary completionActual
Feb 7, 2026
CompletionActual
Feb 7, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07043283
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Oct 20, 2025
Primary completion
Feb 7, 2026
Completion
Feb 7, 2026
Last update
Jun 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebronucimab

Start the discussion